

Edgar Filing: CRITICAL THERAPEUTICS INC - Form 8-K

CRITICAL THERAPEUTICS INC

Form 8-K

October 17, 2006

=====

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

-----

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): October 17, 2006

Critical Therapeutics, Inc.  
(Exact Name of Registrant as Specified in Charter)

|   |                             |                                      |
|---|-----------------------------|--------------------------------------|
| Delaware  | 000-50767                   | 04-3523569                           |
| (State or Other Jurisdiction<br>of Incorporation) | (Commission<br>File Number) | (IRS Employer<br>Identification No.) |

|  |            |
|--|------------|
| 60 Westview Street, Lexington, Massachusetts | 02421      |
| (Address of Principal Executive Offices)     | (Zip Code) |

Registrant's telephone number, including area code: (781) 402-5700

Not applicable  
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- =====

Item 8.01. Other Events.

Edgar Filing: CRITICAL THERAPEUTICS INC - Form 8-K

On October 17, 2006, Critical Therapeutics, Inc. announced that the U.S. Food and Drug Administration has accepted for filing its New Drug Application for the twice-daily, controlled-release formulation of zileuton, an investigational drug developed for the prevention and chronic treatment of asthma in adults and children 12 years of age and older. A copy of the press release is filed as Exhibit 99.1 attached hereto and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

The Exhibit Index attached to this Report is incorporated herein by reference.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 17, 2006

CRITICAL THERAPEUTICS, INC.

By: /s/ Frank E. Thomas

-----  
Frank E. Thomas  
President

EXHIBIT INDEX

Exhibit No.

Description

-----  
99.1

-----  
Press Release dated October 17, 2006